Jenna Payesko

The study emphasizes the need for harm reduction interventions that include access to syringes and sterile injection equipment, in addition to comprehensive HIV prevention services.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

A first-of-its-kind study found that mortality in the first year after critical illness is higher among older adults with Medicaid insurance compared to those with Medicare and additional commercial insurance, especially among those discharged to skilled-care facilities.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

Lofexidine (LUCEMYRA) safely reduces opioid withdrawal symptoms at 3.2 mg/day and 2.4 mg/day to a clinically meaningful extent, facilitating opioid discontinuation treatment, according to data from a pooled analysis.

Treatment with RBP-7000 significantly reduced Positive and Negative Syndrome Scale (PANSS) total score and greatly increased the percentage of adults with schizophrenia achieving treatment response.

RBP-7000 is an investigational, subcutaneously administered extended-release treatment for schizophrenia.

Lamotrigine (Lamictal) for seizures and bipolar disorder can cause hemophagocytic lymphohistiocytosis (HLH), a rare, but very serious immune system reaction that excessively activates the body’s infection-fighting immune system.

Tolvaptan is the first drug approved to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.

Officials with the FDA have approved the abbreviated new drug application of daptomycin for injection as an antibiotic and generic alternative to Cubicin.

Officials with the FDA granted orphan drug designation for Reviva Pharmaceuticals’ clinical stage drug candidate, RP5063 for treatment of idiopathic pulmonary fibrosis.

FDA to limit distribution of Bayer’s Essure device to guarantee women considering permanent contraception are provided with adequate risk information.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Treatment with sacubitril/valsartan (Entresto) improved several types of physical and social activities in heart failure patients with reduced ejection fraction compared with enalapril.

Exenatide extended-release (Bydureon) approved as an add-on therapy to basal insulin in adults with type 2 diabetes with inadequate glycemic control.

Once-daily, oral investigational depression drug shows insufficient evidence of overall efficacy upon preliminary review.

Gut microbiota alternations have been linked to a variety of life-threatening disorders.

Non-disclosure criminal prosecutions among gay, bisexual and other men who have sex with men have been increasing.

Emergency departments may provide an opportunity to capture those with undiagnosed HIV infection missed by screening programs.

The median time to viral suppression decreased from 63 days to 45 days post-rapid entry program.

Participants receiving semaglutide lost significantly more weight than those receiving placebo after 1 year.

Reducing financial barriers may increase the use of evidence-based treatments and improve adherence to medications.

Findings demonstrated that early use of a low-dose combination blood pressure drug is safe and more effective than current treatments.

The risk of HIV Infection may increase during and after pregnancy, a new study suggests.

The CDC reports that the epidemiologic evidence collected indicates that products reported to be kratom or contain kratom are a likely cause of the outbreak.

Use of drugs that treat attention-deficit/hyperactivity disorder increased among all age groups and in all US geographic regions.

Galcanezumab found to significantly decrease the average number of monthly migraine headache days.

Children with ADHD treated with AKL-T01 showed a significant positive improvement in attention.

Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.